CD8+ T Cell Depletion and Macrophage Modulation in Tumor Models

For CD8⁺ T cell depletion, 200 μg anti-mouse CD8α antibody (clone 2.43, BioXcell) or isotype control (rat IgG2b, BioXcell) was intraperitoneally (i.p.) injected into mice every three days four times in the presence or absence of BF10 cotreatment. The depletion efficacy of CD8 T cells was examined by flow cytometry analysis of mouse peripheral blood samples (pre-bleed and post-bleed) and IHC as indicated. The macrophage depletion was accomplished by intraperitoneal administration of clodronate-Liposome (Liposoma BV, Netherlands) as our previous study.³ (link) Briefly, Tumor-bearing mice were received with clodronate- and/or PBS- liposome solution (200μL contains 1mg clodronate for 20g mice) at the indicated time, followed by co-treatment of IL-10-Fc or BF10 with a three-day interval for tumor growth analysis.